Insider Selling: Adlai Nortye (NASDAQ:ANL) CFO Sells $80,754.75 in Stock

Key Points

• CFO Xiaofeng Ye sold $80,754.75 worth of Adlai Nortye shares, disposing of 5,667 shares at an average price of $14.25. The sale covered tax-withholding obligations tied to vested equity awards and reduced his holdings by 3.69%.
• Adlai Nortye shares rose 9.5% to $15.05, with the stock trading between a 52-week low of $0.88 and high of $17.25.
• Analysts maintain a generally positive view, with five Buy ratings and one Sell rating, producing a “Moderate Buy” consensus and an average price target of $24.25. Institutional investors and hedge funds own 35.21% of the company.

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL - Get Free Report) CFO Xiaofeng Ye sold 5,667 shares of the firm's stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $14.25, for a total value of $80,754.75. Following the sale, the chief financial officer directly owned 147,757 shares in the company, valued at $2,105,537.25. This trade represents a 3.69% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xiaofeng Ye also recently made the following trade(s):

• On Monday, August 24th, Xiaofeng Ye sold 6,000 shares of Adlai Nortye stock. The stock was sold at an average price of $13.98, for a total value of $83,880.00.

Adlai Nortye Stock Up 9.5%

ANL traded up $1.31 on Wednesday, reaching $15.05. The company's stock had a trading volume of 147,795 shares, compared to its average volume of 397,755. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.65 and a current ratio of 9.55. Adlai Nortye Ltd. Sponsored ADR has a fifty-two week low of $0.88 and a fifty-two week high of $17.25. The stock has a 50 day moving average of $11.91 and a two-hundred day moving average of $11.13.

Analysts Set New Price Targets

A number of research analysts recently commented on ANL shares. Oppenheimer initiated coverage on shares of Adlai Nortye in a research report on Thursday, May 28th. They issued an "outperform" rating and a $32.00 target price on the stock. JonesTrading started coverage on shares of Adlai Nortye in a research note on Thursday, May 14th. They issued a "buy" rating and a $22.00 price objective for the company. Cantor Fitzgerald began coverage on Adlai Nortye in a report on Monday, June 22nd. They set an "overweight" rating on the stock. Wall Street Zen upgraded Adlai Nortye from a "hold" rating to a "buy" rating in a research report on Saturday. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Adlai Nortye in a report on Tuesday, July 14th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Adlai Nortye has an average rating of "Moderate Buy" and a consensus price target of $24.25.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. SmartHarvest Portfolios LLC raised its holdings in Adlai Nortye by 8.5% during the first quarter. SmartHarvest Portfolios LLC now owns 16,367 shares of the company's stock worth $113,000 after purchasing an additional 1,279 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in Adlai Nortye in the 1st quarter valued at approximately $457,000. Seven Fleet Capital Management LP acquired a new position in Adlai Nortye during the 2nd quarter worth approximately $1,302,000. ADAR1 Capital Management LLC acquired a new position in Adlai Nortye during the first quarter worth $816,000. Finally, Affinity Asset Advisors LLC acquired a new position in shares of Adlai Nortye during the 1st quarter worth $1,140,000. 35.21% of the stock is currently owned by institutional investors and hedge funds.

About Adlai Nortye

Adlai Nortye Inc NASDAQ: ANL is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source